Smith & Nephew SNATS (SNN) Projected to Post Quarterly Earnings on Tuesday

Smith & Nephew SNATS (NYSE:SNN) is expected to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Smith & Nephew SNATS to post earnings of $1.17 per share and revenue of $1.6754 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 3:30 AM ET.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock opened at $36.94 on Friday. The company has a 50-day moving average of $34.16 and a two-hundred day moving average of $34.97. Smith & Nephew SNATS has a 12-month low of $23.91 and a 12-month high of $38.79. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60.

Hedge Funds Weigh In On Smith & Nephew SNATS

Institutional investors have recently modified their holdings of the company. Arax Advisory Partners boosted its position in Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Smith & Nephew SNATS in the fourth quarter valued at $43,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Smith & Nephew SNATS by 105.8% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 1,385 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 712 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on SNN shares. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Canaccord Genuity Group dropped their price target on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS has an average rating of “Hold” and a consensus target price of $35.75.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.